The 16th episode of our podcast, Disrupt, is now available!
Since joining Amedisys (Nasdaq: AMED) in 2014, CEO Paul Kusserow has spearheaded an ambitious turnaround effort, during which time the company’s stock has climbed from around $20 per share to the $130 per share range it sits at today.
Most of Amedisys’ growth over the years has come organically, though the Baton Rouge, Louisiana-based company has been active on the M&A front as well, reflected by its two recent hospice deals.
Listen to this episode of Disrupt to learn:
- What Amedisys is doing to prepare for PDGM
- How the company has grown over the last four years
- Why Amedisys is becoming an even bigger hospice player
- … And much more!
Subscribe to Disrupt to be notified when new episodes are released. Listen today!
Disrupt is exclusively sponsored by